Pearce IP BioBlast: w/e 14 Feb 2020

 

  • On 11 February 2020, Amgen sued Hospira in the District Court of Delaware, alleging Hospira's aBLA for a proposed pegfilgrastim biosimilar infringes Amgen's Neulasta patent for protein purification (no. 8,273,707).

 

 

Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

August 19, 2020

Please reload

Search by tags
Please reload